Kornimate/medical-research-clean huggingface dataset:
efficacy of formoterol vs ipatropioum bromide plus fenoterol in children (5-<12 years) with acute bronchial obstruction

Conditions: Acute Bronchial Obstruction, Asthma

Summary: to determine efficacy and tolerability of inhaled formoterol vs nebulized ipatropioum bromide plus fenoterol in cumulative sequential doses in asthmatic children (5-\<12 years) with acute bronchial obstruction attending emergency services


Eligibility criteria:
inclusion criteria: * asthmatic children 5-\<12 years old, requiring emergency services for acute bronchial obstruction mild to moderate determined by functional and clinical evidence exclusion criteria: * patients with severe acute bronchial obstruction determined by functional and clinical evidence * patients unable to use the inhaling device at time of treatment * patients who received a bronchodilator drug within the last 12 hours * patients who received inhaled steroids within the last 72 hours * patients who received systemic steroids within the last 7 days * patients with near fatal asthma history * patients with fever (\>38.5°c axillar temp) * patients with any clinical significance condition other protocol-defined inclusion/exclusion criteria may apply

Keywords: asthma, formoterol, bronchial obstruction, children
trial of the use of doxycycline after rotator cuff repair

Conditions: Rotator Cuff Injury

Summary: the purpose of this study is to examine healing after rotator cuff repair in subjects either treated with doxycycline or placebo post-operatively.

basic science small animal model data indicates that matrix metalloproteinase (mmp) inhibition via doxycycline results in improved early rotator cuff repair biomechanics and histology. rotator cuff repair failure and retear is a significant clinical problem. the effects of mmp inhibition on human rotator cuff tear repair healing and outcomes is unknown, but may potentially improve healing rates and outcomes. our purpose is to evaluate the effects of early oral doxycycline on healing and outcomes following arthroscopic rotator cuff repair.

Eligibility criteria:
inclusion criteria: * repair of rotator cuff * age 18 and above * able to swallow capsules exclusion criteria: * less than 18 * unable to read or understand consent form * unable to swallow capsules * allergy to doxycycline

Keywords: rotator cuff repair doxycycline
the early diagnosis of pulmonary nodule based on multi-dimension messages

Conditions: Pulmonary Nodule, Solitary; Lung; Node

Summary: the researchers are aimed to investigate the early diagnosis of pulmonary nodule based on dna, rna, protein, metabolites through analyzing the serum, plasma, urine, faeces, peripheral blood mononuclear cell (pbmc), exhaled breath condensate and clinical characteristics.

by recruiting people with pulmonary nodules identified by ct scans, three groups are confirmed as the lung cancer group, the benign lung nodule group who are identified by pathological analysis, and the small lung nodule group that should be followed up. then the serum, plasma, urine, faeces, peripheral blood mononuclear cell (pbmc), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, bmi, address, greening environment and the laboratory tests are collected to analyze the ctdna, rna, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.

Eligibility criteria:
inclusion criteria: for lung cancer groups * (1) patients diagnosed with lung cancer; * (2) clear diagnosis by pathological examination to determine pathological type; * (3) those aged 18-80 years old; * (4) for patients with newly diagnosed lung cancer, ct confirmed that the size of primary lung cancer is ≤ 3 cm; * (5) the patient or family member agrees to participate in the study and sign an informed consent form; * (6) no other serious cardiopulmonary diseases. for lung nodule * (1) those aged 18-80 years; * (2) ct clear lung nodule size ≤ 3cm; * (3) 1-3cm pulmonary nodules confirmed by pathological diagnosis as non-lung cancer or other metastatic cancer patients or ≤1cm pulmonary nodules * (4) the patient or family member agrees to participate in the study and sign an informed consent form; * (5) no other serious cardiopulmonary diseases. exclusion criteria: * (1) women who are breast-feeding, pregnant or preparing for pregnancy; * (2) those who are allergic to allergies and multiple drugs; * (3) combining severe primary diseases such as cardiovascular and cerebrovascular, liver, kidney, and hematopoietic system, as well as subjects with mental illness; * (4) concurrently infected; * (5) those who participated in other clinical trials within three months.
the prevelence of ivs 1-6 (t-c) [hbb:c.92 +6 t-c] gene mutation in suspected cases of β thalassemia in assiut university hospitals

Conditions: Beta-Thalassemia

Summary: 1. - to design an amplification-refractory mutation system (arms) for the dna diagnosis of the ivs i-6 (t\>c) mutation. 2. - to detect the prevelence of the mutation among assiut university hospital patients. 3. - phenotype/genotype correlation of the mutation.

• the β-thalassaemias result from 300 gene mutations ( https://globin.bx.psu.edu ). all of the mutations are regionally specific and the spectrum of mutations has now been determined for most at-risk populations(old jm, 2007). * the strategy for identifying β-thalassaemia mutations is usually based on the knowledge of the common and rare mutations in the ethnic group of the individual being screened.(old jm, 2007) . * in mediterranean it represnts 8-15% * in africa it represnts 3.5% * in egyptians it represnts 13.6% ( https://globin.bx.psu.edu ). * the β globin gene mutation ivs i-6(t\>c) is the first most common β globin gene mutation among egyptians * (36.3%) according to ( somaia el-gawhary et al 2007 ) * (27.66%) ( ammar d. elmezayen et al 2015 ) * and the second most common mutation * (40%) according to ( el-shanshory m et al 2014) * (21.25%) ( elhalfawy et al 2017) the molecular characterization of the globin gene mutation is necessary for definite diagnosis, genetic counseling, and to offer prenatal diagnosis. the amplification-refractory mutation system (arms) is a simple method for detecting any mutation involving single base changes or small deletions. * the dna is analysed after amplification by pcr for detection of point mutation ivs i-6(t\>c) by using primer pairs that only amplify individual alleles \[arms\] .

Eligibility criteria:
inclusion criteria: * : β thalassemia (suspected \& clinically diagnosed cases). exclusion criteria: * : iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias other than thalassemia, other types of thalassemia and hb variants
knowledge attitude and practice regarding bloodstream bacterial infections and antibiotics usage among doctors.

Conditions: Bacteremia; Antimicrobial Stewardship; Antibiotic Use; Antibiotic Abuse

Summary: this study is designed to use a questionnaire to assess doctors' knowledge, attitudes, and practices regarding bloodstream bacterial infections and antibiotic use in tawam and al ain tertiary hospitals (both hospitals have the same medical team) in al ain city, uae.

background: bloodstream bacterial infection is a serious medical problem and one of the leading causes of death worldwide among all age groups. appropriate and early antibiotic use has been associated with better outcomes based on many clinical trials. on the other hand, misuse and abuse of antibiotics have been linked to long hospital stays, significant morbidity and mortality, increased medical costs and rising antimicrobial resistance (amr). statistics in hospitals involved in the study, showed increased antibiotic consumption compared to previous years and other regional healthcare facilities. rates of amr in the uae have increased significantly in the last decade, based on the 2022 annual report. aims and objectives this study will assess knowledge, attitude and practice regarding bloodstream bacterial infections and antibiotics use among doctors. it is a questionnaire-based cross-sectional descriptive study that will be conducted at tawam and al ain hospitals (tertiary hospital, both hospitals have the same medical team). the investigators want to explore the degree of knowledge and attitude, assess the appropriate usage of antibiotics among doctors in different subspecialties, assess any possible barriers, and find solutions such as medical education for this challenging medical problem.

Eligibility criteria:
inclusion criteria: all physicians with valid medical licenses working in tawam and al ain tertiary hospitals exclusion criteria: infectious diseases physicians and microbiologists

Keywords: bacteremia antimicrobial resistance antimicrobial stewardship healthcare workers antibiotic use antibiotic abuse
a 24-week study of the efficacy and safety of blu-5937 in adults with refractory chronic cough

Conditions: Cough; Refractory Chronic Cough

Summary: this is a randomized, double-blind, placebo-controlled, parallel-arm, phase 3 study of blu-5937 in participants with refractory chronic cough (rcc).

the primary efficacy objective is to assess the effect of blu-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.

Eligibility criteria:
inclusion criteria: * capable of giving signed informed consent * refractory chronic cough (including unexplained chronic cough) for at least one year * women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose exclusion criteria: * current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment * respiratory tract infection within 4 weeks before screening * laboratory confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection at screening * history of malignancy in the last 5 years * history of alcohol or drug abuse within the last 3 years * has a positive serologic test for human immunodeficiency virus (hiv), hepatitis b virus surface antigen, or hepatitis c virus. * previous participation in a blu-5937 trial

Keywords: respiration disorders respiratory tract diseases signs and symptoms, respiratory cough chronic cough
extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult bile duct stones

Conditions: Bile Duct Stenosis

Summary: when conventional endoscopic treatment of bile duct stones is impossible or fails, advanced endoscopy assisted lithotripsy can be performed by electrohydraulic lithotripsy (ehl), laser lithotripsy, or extracorporeal shock wave lithotripsy (eswl). no systematic review has compared efficacy and safety between these techniques.

extracorporeal shock wave lithotripsy (eswl) and laser lithotripsy (ll) have emerged as alternate treatment options for difficult common bile duct (cbd) stones. there is limited data on efficacy and safety of the latest dornier delta iii lithotripter. this study examined the efficacy of eswl by dornier delta iii \& laser lithotripsy in terms of stone clearance rate, number of sessions required and safety in a large cohort of patients. the initial lithotripter models used electrohydraulic energy and required general anesthesia, prone positioning, and water immersion. high clearance rates were reported, but newer models were then developed with use of electromagnetic coils, better focussing, use of a water cushion instead of water immersion, use of ultrasound and then later of digitalised x ray for localisation. the ductal clearance of eswl is upto 90%. known complications of this procedure are cholangitis and pancreatitis which occur at the rate of 9-14% apart from minor adverse effects such as pain and local hematoma formation. in a single randomised study that compared intracorporeal lithotripsy(ill) versus extracorporeal lithotripsy, ill was found more effective than eswl in terms of stone clearance rate and treatment duration. however, the lithotripters used in the previous studies were of previous generations, and also commonly used for kidney stones as well. the current study is the first to use the dornier delta iii for the same.

Eligibility criteria:
inclusion criteria: * patients with stones that could not be extracted by conventional methods such as biliary sphincterotomy, balloon, basket or mechanical lithotripsy. * patients with biliary stones larger than 15mm. * intrahepatic or cystic duct stones. exclusion criteria: * pregnancy. * coagulopathy which cannot be corrected. * ongoing cholangitis.
collaborative study of neurofeedback training of 6-18 year olds with autism

Conditions: Autism

Summary: neurofeedback, a neuro-cognitive training method based on operant conditioning, will be employed with 90 children with the autistic spectrum disorders (asd) over a 60 session training period to improve the limiting behavioral and sensory symptoms autism presents (with each collaborative site working with 45 of the 90 participants). this study seeks to demonstrate that neurofeedback training, a non-invasive approach based on learning theory, will mitigate presenting symptoms of autism, and ultimately render the person with autism significantly more able to interact with his/her environment successfully, independently function on a day-to-day basis, and improve overall mental health.

the specific objective is to demonstrate quantitative and qualitative improvements in functional and behavioral parameters in individuals affected by autism spectrum disorders when 60 neurofeedback training sessions are applied. the long term objectives for these individuals include improvement of quality of daily functioning, better ability to integrate and navigate within society, and overall to decrease the limitations caused by the disability. additionally, increasing awareness by the public, as well as healthcare providers and legislation, that neurofeedback is a viable intervention which may contribute not only to a significant reduction of the level of disability for affected individuals, but also in reducing required lifetime costs of healthcare. hopefully in the future neurofeedback training would be incorporated as a standard of care for asd. as of today, there are around 1000 trained neurofeedback practitioners in the us who are offering this intervention to a very limited number of individuals due to lack of recognition of nfb benefits.

Eligibility criteria:
inclusion criteria: * 6 to 18 year olds who have been diagnosed by their physician with mild to moderate autism, in accordance with dsm-iv diagnostic criteria exclusion criteria: * any child with a diagnosis of bipolar disorder, tourette's syndrome, an uncontrolled seizure disorder, or a history of any major psychiatric disorder will be excluded from eligibility for the study.

Keywords: neurofeedback braintraining autism mild moderate mild to moderate autism
influence of simple renal cysts on renal function

Conditions: Simple Renal Cyst; Renal Function Disorder

Summary: this is a prospective, cohort, randomized clinical trial examining the effect of simple renal cysts on renal function.

this study is planned to include patients from s.i. spasokukotskiy citi clinical hospital with simple renal accidentally discovered cyst. the aim of the study is to evaluate the impact of simple renal cysts on renal function and explore the correlation between cyst's size, parenchymal atrophy, and renal function. after receiving the results, the analysis of the data obtained is carried out. 1. the symmetry of the function of both kidneys is analyzed 2. the relationship between the presence of a simple kidney cyst and a decrease in its function in comparison with a healthy kidney is analyzed. 3. the relationship between the maximum size of a kidney cyst and a decrease in its function in comparison with a healthy kidney is analyzed. 4. the relationship between the volume of the atrophied kidney parenchyma and a decrease in its function as compared with a healthy kidney is analyzed. 5. correspondence of gfr indices obtained by scintigraphy and by calculation using the schwartz formula

Eligibility criteria:
inclusion criteria: * adult patients with simple kidney cyst bosniak 1-2 * normal blood creatinine values exclusion criteria: * impossibility of performing ct with intravenous contrast enhancement. * bosniak 3-4 * ckd * bilateral cysts * multiple renal cysts * sinus cysts * cysts with a max size less than 2 cm. * single kidney * chronic kidney disease and conditions associated with the potential decrease of kidney function * glomerulonephritis * chronic pyelonephritis * amyloidosis * diabetes * autoimmune diseases * urolithiasis * kidney and upper urinary tract surgery * anomalies of the kidneys and upper urinary tract with impaired outflow * calcification of the renal arteries * renal artery stenosis * hypertensive nephropathy * severe concomitant diseases requiring * chemotherapy * long-term (more than 10 days) antibiotic therapy in the last month * long-term (more than 7 days) use of nsaids in the last month * diagnostic and therapeutic manipulations accompanied by the introduction of x-ray contrast agents * secondarily shriveled or non-functioning kidney * kidney hypoplasia * accessory kidney * a decrease in gfr below normal values for a kidney without a cyst (as determined by nephroscintigraphy)

Keywords: simple renal cyst, renal function
markers of appetite regulation during exogenous ketosis

Conditions: Ketosis

Summary: the aim of this study is to investigate the relationship, if any, between markers of satiety, desire to eat, hunger, and metabolic markers of the regulation hereof during ketosis as compared with a glucose-containing and a placebo drink adjusted for taste.

all subjects are, in random order, tested on three separate occasions with intake of weight adjusted and taste matched drink of i) a ketone ester, and ii) an isocaloric and -volumetric glucose drink, or iii) an isovolumetric tap water drink. subjects are studied for five hours with baseline and blood sampling on multiple occasions. a satiety questionaire are included. subjects are recruited through notice on website for this purpose. sample size calculations were performed prior to inclusion (n=10). according to protocolized statistical plan, missing data will not be replaced and no imputation will occur. data will be analyzed by applying a repeated measurements multilevel model with intervention, time and their interactions as categorical factors. effects size are adjusted for small sample size.

Eligibility criteria:
inclusion criteria: * males aged 18-65 years * bmi 20-35 kg/m2 * expected ease of catheter insertion * oral and written informed consent exclusion criteria: * inability to fully understand the consent including consent forms * inability to cooperate to the trial * any electrolyte disorders, kidney disease or otherwise compromised renal function including excess risk hereof, e.g. hypertension, albuminuria, autoimmune disease, family history of kidney disease * any liver or bile disease including excess risk hereof, e.g. hepatotoxic drugs, alcohol abuse disorder, gallstones, pancreatitis, autoimmune disease, family history of liver disease * diabetes mellitus or any metabolic and/or hormonal disease including diagnosed/undiagnosed reactive hypoglycemia or similar disorders. this includes treatment with drugs, dietary supplement with inference on key metabolic or hormonal markers, e.g. insulin, glukagon, lipids, and glp-1 * any use of illegal or otherwise use of medicinal products without prescription * anemia or other know disease of the hematopoietic system * previous bariatric surgery * previous myocardial infarction or uncontrolled myocardial ischemia * recent intended/unintended weight loss * allergies to catheters or adhesives
a study of met233 in individuals with obesity or overweight

Conditions: Obesity and Overweight

Summary: the goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of met233 in otherwise healthy adults with overweight or obesity. the trial will be conducted in three parts. part a consists of single ascending dose (sad) cohorts of met233 or placebo. part b consists of multiple ascending dose (mad) cohorts, with participants treated with five once-weekly doses of met233 or placebo. in part c, participants will receive once-weekly doses of met233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.

this is a randomized, placebo-controlled, double-blind study designed to investigate the safety, tolerability, pk and pharmacodynamic (pd) of single and multiple ascending subcutaneous (sc) doses of met233 in otherwise healthy adult participants with obesity or overweight (body mass index \[bmi\] 27.0 kg/m2 to 38.0 kg/m2, inclusive). in part a, approximately 40 participants will receive a single dose of met233 at up to 5 dose levels. in part b, approximately 40 participants will receive five weekly doses of met233 at up to 4 dose levels. in part c, up to 4 cohorts of 10 participants each will receive 12 weekly doses. these doses may include titration. for all cohorts in part c, the 13th dose of met233 administered on day 85 may be a monthly-equivalent dose to allow evaluation of a potential to switch to a monthly dosing regimen.

Eligibility criteria:
inclusion criteria: * adult (≥18 to ≤70 years) male and female participants with obesity or overweight (bmi 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy. exclusion criteria: * female who is lactating or who is pregnant according to the pregnancy test at the screening visit or prior to the first study drug administration * seated blood pressure higher than 160/95 mmhg at the screening visit * elevated resting pulse greater than 100 beats per minute at screening visit * presence of clinically significant ecg abnormalities * diagnosis of diabetes (type 1 or type 2) * participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration * obesity induced by endocrinologic disorders (e.g., cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or prader-willi syndrome).